Camptothecin ADC Derivatives for Wider Therapeutic Windows
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody-drug conjugates (ADCs) using camptothecin derivatives, such as exatecan, face challenges with severe side effects and narrow therapeutic windows due to high toxicity and reduced Drug-Antibody-Ratio (DAR), limiting their effectiveness and safety in treating various cancers.
Innovation Solution
Development of camptothecin derivatives with molecular structure modifications to enhance anti-tumor activity and reduce toxicity, forming antibody-drug conjugates with improved therapeutic indices, specifically through the design and synthesis of camptothecin derivatives and their antibody conjugates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If camptothecin derivatives such as exatecan are used as ADC toxins, then anti-tumor activity is achieved, but severe side effects and narrow therapeutic window occur due to high toxicity
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of camptothecin derivatives through substitution at different positions (C-1, C-7, C-10, N-1) with various functional groups (alkyl, aryl, heteroaryl, deuterium). These structural parameter changes result in derivatives with improved therapeutic indices, reduced toxicity, and enhanced stability while maintaining anti-tumor activity against topoisomerase-I
Solution Approach 2:
The patent applies local quality by introducing specific substituents at particular positions on the camptothecin core structure. Each substitution position and type is optimized to achieve localized improvements in drug properties - for example, deuterium substitution at specific positions enhances metabolic stability, while specific aryl or heteroaryl groups at C-10 position improve binding affinity to topoisomerase-I, thereby reducing required dosage and side effects
2Object-affected harmful factors
If Drug-Antibody-Ratio (DAR) is reduced to improve safety, then therapeutic index decreases, but high DAR increases toxicity
Solution Approach 1:
The patent resolves this contradiction through parameter changes in the drug molecule itself - by optimizing the camptothecin derivative structure to achieve better potency and selectivity, the required DAR can be reduced while maintaining therapeutic index. The improved derivatives allow lower drug loading (reduced DAR) to achieve the same therapeutic effect with less toxicity
Solution Approach 2:
The patent creates optimized copies of the original camptothecin structure with improved properties. These derivative copies maintain the core mechanism of action against topoisomerase-I but incorporate modifications that enhance selectivity and reduce off-target effects, allowing for safer ADC designs with optimized DAR
Data Source
AI summary
An antitumor pharmaceutical camptothecin derivative and an antibody-drug conjugate thereof. By means of a series of molecular structure modifications, an optimal camptothecin antitumor drug is obtained, so as to be more suitable as a drug for antibody conjugation.